Back to Posts

Back to Posts

June 23, 2022 Agency Alerts

FDA revises 2013 guidance – Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination


Draft Guidance

June 2022

FDA is announcing the availability of a draft guidance titled, “Non-Penicillin Beta-Lactam Drugs:  A CGMP Framework for Preventing Cross-Contamination.” This guidance revises the final guidance of the same title issued on April 17, 2013, and expands the scope of the guidance to include all compounds containing a beta-lactam ring in their structure. All beta-lactam compounds, including non-penicillin beta-lactam antibacterial drugs as well as non-antibacterial beta-lactam compounds (including intermediates and derivatives), have the potential to cause allergic reactions and represent a life-threatening risk to certain patients.

This draft guidance describes methods, facility design elements, and controls that are important in preventing drugs from being cross-contaminated with non-penicillin beta-lactam antibacterial drugs or non-antibacterial beta-lactam compounds and makes recommendations for how manufacturers can be compliant with current good manufacturing practice requirements for preventing cross-contamination. This guidance also provides information regarding the relative health risk of, and the potential for, allergic reactions due to cross-reactivity in the classes of non-penicillin beta-lactam antibacterial drugs and non-antibacterial beta-lactam compounds.

This guidance recommends manufacturers have complete and comprehensive separation between non-penicillin beta-lactam antibacterial drugs and manufacturing operations of other drugs. For manufacturers of non-antibacterial beta-lactam compounds, this guidance provides recommendations on cross-contamination prevention strategies, including examples of relevant design features and control approaches for those seeking to justify a cross-contamination prevention strategy other than complete and comprehensive separation, when appropriate.

Significant changes from the 2013 guidance include:

  • Clarifying that the scope of the guidance also includes all compounds, including intermediates or derivatives, that are not a penicillin, have a chemical structure that includes one or more beta-lactam rings, and have a mechanism of action other than an antibacterial mechanism of action
  • Providing FDA’s interpretation of terms, such as allergic reaction, cross-reactivity, and complete and comprehensive separation, used in this guidance
  • Clarifying the distinction between non-penicillin beta-lactam antibacterial drug(s) and non-antibacterial beta-lactam compound(s)–in terms of the cross-contamination and patient exposure risks and the control strategies appropriate for manufacturing operations involving each category
  • Providing recommendations for drug manufacturers that seek to justify alternative cross-contamination prevention strategies for non-antibacterial beta-lactam compounds

Download the Draft Guidance

Interested in learning more? Contact us today to find out how we can help with your global regulatory needs.



Your Business has Complex Challenges. ProPharma Group has Exceptional Solutions.

We partner with pharmaceutical, biotechnology, and medical device clients to tackle complex challenges. Contact us to learn how our experienced team can help ensure regulatory and development success throughout the product lifecycle.

Interested in gaining an industry edge? Let us help you stay up to date.


All fields are required.
There was a problem with your submission. Errors have been highlighted below.